Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

被引：0
|
作者：
Blanco, Alberto [1 ]
Chari, Ajai [2 ]
Martin, Thomas G. [2 ]
Arora, Shagun [2 ]
Chung, Alfred [2 ]
Kumar, Anupama Deepa [2 ]
Shah, Nina [2 ]
Wong, Sandy W. [2 ]
Takamatsu, Hiroyuki [3 ]
Martinez-Lopez, Joaquin [1 ]
Wolf, Jeffrey Lee [2 ]
机构：
[1] Hosp Univ 12 Octubre, Dept Hematol, Madrid, Spain
[2] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA USA
[3] Kanazawa Univ, Dept Hematol, Kanazawa, Japan
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203768
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7020 / 7021
页数：2
相关论文
共 50 条
  • [41] Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
    Liu, Jiahui
    Yan, Wenqiang
    Fan, Huishou
    Xu, Jingyu
    Li, Lingna
    Du, Chenxing
    Mao, Xuehan
    Yan, Yuting
    Xu, Yan
    Sui, Weiwei
    Deng, Shuhui
    Yi, Shuhua
    Anderson, Kenneth C.
    Qiu, Lugui
    Zou, Dehui
    An, Gang
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1770 - 1780
  • [42] Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma
    Gordan, Lucio
    Warner, Amanda
    Heritage, Trevor
    Ming, Amy
    Gupta-Werner, Niodita
    Kaila, Shuchita
    Cortoos, Annelore
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S137 - S137
  • [43] Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma
    Gordan, Lucio N.
    Warner, Amanda
    Heritage, Trevor
    Ming, Amy
    Gupta-Werner, Niodita
    Kaila, Shuchita
    Cortoos, Annelore
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S546
  • [44] Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
    Ravi, Gayathri
    Giri, Smith
    Bal, Susan
    Godby, Kelly N.
    Reddy, Vishnu V. B.
    Salzman, Donna
    Alkharabsheh, Omar
    McDaniel, Scott A.
    Sentell, Melissa
    Costa, Luciano J.
    BLOOD, 2022, 140 : 8048 - 8049
  • [45] Efficacy of VDT PACE-like Regimens in Treatment of Relapsed / Refractory Multiple Myeloma-a Single Center Experience
    Lakshman, Arjun
    Singh, Preet Paul
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Dingli, David
    Dispenzieri, Angela
    Hwa, Lisa
    Fonder, Amie
    Hobbs, Miriam
    Zeldenrust, Steven
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Kapoor, Prashant
    Kourelis, Taxiarchis
    Warsame, Rahma
    Kyle, Robert A.
    Kumar, Shaji K.
    BLOOD, 2017, 130
  • [46] Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
    Avet-Loiseau, Herve
    San-Miguel, Jesus
    Casneuf, Tineke
    Iida, Shinsuke
    Lonial, Sagar
    Usmani, Saad Z.
    Spencer, Andrew
    Moreau, Philippe
    Plesner, Torben
    Weisel, Katja
    Ukropec, Jon
    Chiu, Christopher
    Trivedi, Sonali
    Amin, Himal
    Krevvata, Maria
    Ramaswami, Priya
    Qin, Xiang
    Qi, Mia
    Sun, Steven
    Qi, Ming
    Kobos, Rachel
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (10) : 1139 - +
  • [47] Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT
    Baker, David
    Bimali, Milan
    Carrillo, Luis
    Sachedina, Archana
    Alapat, Daisy
    Hoque, Md Shadiqul
    Kottarathara, Mathew
    Parikh, Richa
    Erra, Amani
    Mitma, Angel
    Mathur, Pankaj
    Tricot, Guido
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Schinke, Carolina D.
    BLOOD, 2020, 136
  • [48] Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
    Parrondo, Ricardo D.
    Sam, Keren
    Rasheed, Ahsan
    Alegria, Victoria
    Sher, Taimur
    Roy, Vivek
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [49] Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
    Boncompagni, Riccardo
    Staderini, Michela
    Nozzoli, Chiara
    Antonioli, Elisabetta
    Caporale, Roberto
    Peruzzi, Benedetta
    Cutini, Ilaria
    Gozzini, Antonella
    Serena, Mariotti
    Guidi, Stefano
    Jance, Blerina
    Accogli, Barbara
    Francesco, Annunziato
    Bosi, Alberto
    Saccardi, Riccardo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E172 - E172
  • [50] Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
    Galimberti, S
    Benedetti, E
    Morabito, F
    Papineschi, F
    Callea, V
    Fazzi, R
    Stelitano, C
    Andreazzoli, F
    Guerrini, F
    Ciabatti, E
    Martino, M
    Nobile, F
    Iacopino, P
    Petrini, M
    LEUKEMIA RESEARCH, 2005, 29 (08) : 961 - 966
12345